Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter

被引:29
作者
Yu, D
Jia, WW
Gleave, ME
Nelson, CC
Rennie, PS
机构
[1] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
[2] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada
关键词
prostate cancer; androgen regulation; tissue-specific promoter; retrovirus;
D O I
10.1002/pros.20010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Lentiviruses are retroviruses that can infect and stably integrate into the chromatin of non-dividing cells. The purpose of this study was to determine whether lentiviral vectors containing the probasin (PB) promoter displayed prostate-specific, androgen-regulated, and persistent gene expression. METHODS. Three lentiviral-PB promoter/enhanced green fluorescent protein (EGFP)-reporter vectors together with a control lentiviral-CMV-EGFP, were tested by microscopy and flowcytometry for expression of EGFP after infection of human prostate cancer cells (LNCaP, PC-3, PC-3(hAR), and Du145 cells) and non-prostate cells (COS-1, HeLa, HeLa(hAR), and MCF-7 cells). RESULTS. All cells infected in vitro with lentiviral-CMV vectors expressed EGFP, whereas with lentiviral-PB vectors (the most potent being Lv-ARR(2)PB), reporter expression was only observed in LNCaP cells with a small amount seen in androgen-independent PC-3 cells. Stable or transient transfection of androgen receptor only raised EGFP expression in prostate-derived cell lines, but did not change tumor specificity. With Lv-ARR(2)PB infected LNCaP cells, androgens regulated EGFP both in vitro and in vivo. After intra-tumor injection of this vector, EGFP expression was observed in LNCaP tumors, but not in A-549 lung or CaKi-2 kidney tumors. CONCLUSIONS. Lv-ARR(2)PB may be an ideal vector for prostate-tumor targeting and for persistent, hormone-enhanced expression of a therapeutic gene to treat slow growing prostate tumors. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:370 / 382
页数:13
相关论文
共 47 条
[21]  
KASPER S, 1994, J BIOL CHEM, V269, P31763
[22]  
Klotz Laurence, 2000, Cancer, V88, P3009, DOI 10.1002/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO
[23]  
2-E
[24]  
Koivisto P, 1997, CANCER RES, V57, P314
[25]  
Latham JPF, 2000, CANCER RES, V60, P334
[26]   The expression of prostate-specific membrane antigen in peripheral blood leukocytes [J].
Lintula, S ;
Stenman, UH .
JOURNAL OF UROLOGY, 1997, 157 (05) :1969-1972
[27]  
Long RJ, 1997, J ANDROL, V18, P15
[28]   Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells [J].
Lowe, SL ;
Rubinchik, S ;
Honda, T ;
McDonnell, TJ ;
Dong, JY ;
Norris, JS .
GENE THERAPY, 2001, 8 (18) :1363-1371
[29]   PROSTATE AND MAMMARY ADENOCARCINOMA IN TRANSGENIC MICE CARRYING A RAT C3(1) SIMIAN-VIRUS-40 LARGE TUMOR-ANTIGEN FUSION GENE [J].
MAROULAKOU, IG ;
ANVER, M ;
GARRETT, L ;
GREEN, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11236-11240
[30]   Transcription-targeted gene therapy for androgen-independent prostate cancer [J].
Martiniello-Wilks, R ;
Tsatralis, T ;
Russell, P ;
Brookes, DE ;
Zandvliet, D ;
Lockett, LJ ;
Both, GW ;
Molloy, PL ;
Russell, PJ .
CANCER GENE THERAPY, 2002, 9 (05) :443-452